

19



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Publication number:

**0 336 544
A1**

12

EUROPEAN PATENT APPLICATION

21 Application number: 89301800.2

51 Int. Cl.⁴: **C07D 409/12 , C07D 405/12 ,
C07D 401/12 , A61K 31/47**

22 Date of filing: 23.02.89

Claims for the following Contracting States: ES
+ GR.

The title of the invention has been amended
(Guidelines for Examination in the EPO, A-III,
7.3).

30 Priority: 25.02.88 GB 8804447

43 Date of publication of application:
11.10.89 Bulletin 89/41

64 Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE


71 Applicant: **SMITHKLINE BECKMAN
INTERCREDIT B.V.
28-34 Blaak P.O. Box 2
NL-3000 DG Rotterdam(NL)**

72 Inventor: **Ife, Robert John
9 Edmonds Drive Aston Brook
Stevenage Hertfordshire(GB)
Inventor: Leach, Colin Andrew
30 Wellington Road
Stevenage Hertfordshire(GB)
Inventor: Brown, Thomas Henry
17 Godfries Close
Tewin Hertfordshire(GB)**

74 Representative: **Giddings, Peter John, Dr. et al
Smith Kline & French Laboratories Ltd.
Corporate Patents Mundells
Welwyn Garden City Hertfordshire AL7
1EY(GB)**

54 Heteroaryl 4-amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion.

57 Compounds of structure (I)



in which R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxylC₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, phenyl or phenylC₁₋₆alkyl, the phenyl groups being optionally substituted; R² is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂H or CO₂C₁₋₆alkyl; m is 1, 2 or 3; p is 0 to 4; R³ is hydrogen, C₁₋₆alkyl, phenyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, di-C₁₋₆alkylamino,

EP 0 336 544 A1


halogen, trifluoromethyl or cyano; n is 1 or 2; and X is S, O, NH or NC₁₋₄alkyl; processes for their preparation, intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy as anti-ulcer agents.

Compounds

The present invention relates to novel substituted quinoline derivatives, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy.

Substituted quinoline derivatives having activity as inhibitors of gastric acid secretion are known in the art. In particular, US 4343804 and EP 259174-A disclose series of compounds in which the 4-position of the quinoline ring is substituted by a phenylamino ring which itself may be optionally substituted. The present invention relates to quinoline compounds which are substituted by alternative novel substituents in the 4-position of the quinoline ring and which have also been found to be potent inhibitors of gastric acid secretion.

Accordingly, the present invention provides, in a first aspect, a compound of structure (I) :



in which

R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, phenyl or phenylC₁₋₆alkyl, the phenyl groups being optionally substituted;

R² is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂H or CO₂C₁₋₆alkyl;

m is 1, 2 or 3;

p is 0 to 4;

R³ is hydrogen, C₁₋₆alkyl, phenyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, di-C₁₋₆alkylamino, halogen, trifluoromethyl or cyano;

n is 1 or 2; and

X is S, O, NH or NC₁₋₄alkyl;

or a salt thereof.

Suitably, R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, phenyl or phenylC₁₋₆alkyl, the phenyl groups being optionally substituted. Preferably R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy or C₁₋₆alkoxyC₁₋₆alkyl. Most preferably R¹ is C₁₋₆alkyl or C₁₋₆alkoxy, in particular C₁₋₆alkyl, such as ethyl, n-propyl or i-propyl.

Suitably R² is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂H or CO₂C₁₋₆alkyl. Preferably R² is hydrogen or C₁₋₆alkyl.

Suitably m is 1 to 3; preferably m is 1 or 2.

Suitably p is 0 to 4; preferably p is 0 or 1; most preferably p is 0.

Suitably, n is 1 or 2 and at least one group R³ is in the 8-position of the quinoline ring. Preferably n is 1 and the group R³ is in the 8-position of the quinoline ring.

Suitably R³ is hydrogen, C₁₋₆alkyl, phenyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or cyano. Preferably R³ is hydrogen, C₁₋₆alkyl or C₁₋₆alkoxy; most preferably, R³ is C₁₋₆alkyl or C₁₋₆alkoxy, for example methyl or methoxy.

Suitably X is S, O, NH or NC₁₋₄alkyl; preferably X is sulphur.

C₁₋₆alkyl groups (either alone or as part of another group) can be straight or branched.

Phenyl C₁₋₆alkyl groups include for example benzyl phenylethyl, phenylpropyl and phenylbutyl groups. In addition also included are such groups in which the alkyl portion is branched e.g. 1-methylbenzyl.


Substituted phenyl and phenyl C₁₋₆alkyl groups R¹ include, for example phenyl groups substituted by 1 to 3 substituents as hereinbefore described for substituted phenyl groups R².

It will be appreciated that compounds of structure (I) in which one or more of R¹ to R³ is a C₃₋₆alkyl group (either alone or as part of another group for example a benzyl or phenethyl group) may contain an asymmetric centre due to the presence of the C₃₋₆alkyl group. Such compounds will exist as two (or more) optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the present invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention.


Compounds of structure (I) can form salts with acids and bases, and in particular form pharmaceutically acceptable acid addition salts with suitable organic and inorganic acids the nature of which will be apparent to persons skilled in the art. For example, pharmaceutically acceptable salts can be formed by reaction with hydrochloric, sulphuric, or phosphoric acids; aliphatic, aromatic or heterocyclic sulphonc acids or carboxylic acids such as for example, citric, maleic or fumaric acids.

In a further aspect, the present invention provides a process for the preparation of a compound of structure (I) which comprises

(a) reaction of a compound of structure (II) with a compound of structure (III) :




(II)



(III)

in which R¹, R², R³, n, m, p, and X are as described for structure (I) and Y is a group displaceable by an amine;

(b) for compounds in which p is 1 to 4, reaction of a compound of structure (IV) with a compound of structure (V):




(IV)



(V)


in which R¹, R², R³, n, m and X are as described for structure (I) and Y¹ is a group displaceable by an amine;

(c) reduction of a compound of structure (VI) :



15 in which R^1 , R^2 , R^3 , n , m , p and X are as described for structure (I); and R^4 is hydrogen or a nitrogen protecting group;

(d) for compounds of structure (I) in which R^1 is other than C_{1-6} alkoxy, oxidation of a compound of structure (VII)



35 in which R^2 , R^3 , p and n are as described for structure (I), $R^{1'}$ is a group R^1 other than C_{1-6} alkoxy and R^4 is hydrogen or a nitrogen protecting group; and thereafter if desired,

- removing any protecting groups;
- converting a group R^1 into another group R^1 ;
- converting a group R^2 into another group R^2 ;
- forming a pharmaceutically acceptable salt.

45 Suitable groups Y displaceable by an amine, include for example, halo moieties, aryl or alkylsulphonates, for example, toluene-*p*-sulphonate or methane sulphonate, alkylthio, alkylsulphonyl, alkylsulphinyl, alkoxy or aryloxy. Preferably X is a halo moiety, for example, chloro or bromo, or aryloxy such as phenoxy.

Suitable leaving groups Y^1 will be apparent to those skilled in the art and include for example a halo moiety, preferably chloro or bromo.

Suitable nitrogen protecting groups R^4 will be apparent to those skilled in the art for example as described in "Protective Groups in Organic Synthesis" T.W. Greene, 1981 (Wiley).


50 The reaction between compounds of structure (II) and compounds of structure (III) is carried out in an organic solvent at a temperature of between ambient and reflux temperature of the solvent used. Suitable solvents include, for example, tetrahydrofuran, dioxan or anisole. Preferably the reaction is carried out at reflux temperature in dioxan as a solvent.

55 The reaction between compounds of structure (IV) and compounds of structure (V) is carried out in an inert organic solvent at a temperature of between ambient and reflux temperature of the solvent used, preferably in the presence of a strong base. Suitable solvents include for example, dimethylsulphoxide or tetrahydrofuran. Suitable bases include, for example, lithium diisopropylamide or dimsyl sodium.

The reduction of a compound of structure (VI) is carried out by for example hydrogenation, over a noble

metal catalyst in a suitable solvent. Suitably the reaction is carried out over a palladium on carbon catalyst in ethanol as a solvent, or using a zinc catalyst in acetic acid.


The compounds of structure (VI) can be prepared from the corresponding compounds of structure (VIII)



20 in which R^1 , R^2 , R^3 , R^4 , n , m , p and X are as hereinbefore described, by reaction with, for example, phosphorus oxychloride.

The oxidation of a compound of structure (VII) is carried out in a suitable solvent in the presence of an oxidising agent. Suitable oxidising agents include, for example, manganese dioxide or chromium trioxide.

25 Suitable interconversions of groups R^1 will be apparent to those skilled in the art, for example compounds of structure (I) in which R^1 is C_2-5 alkyl, C_3-6 cycloalkyl C_2-6 alkyl or optionally substituted phenyl C_1-5 alkyl can be prepared by alkylation of the following compounds of structure (IA) :



in which R^2 , R^3 , m , n and p are as described for structure (I) and R^4 is hydrogen or a nitrogen protecting group.

45 The alkylation of compounds of structure (IA) is carried out in the presence of an alkylating agent in a suitable organic solvent at a temperature of between ambient and reflux temperature of the solvent used in the presence of a strong base. Suitable alkylating agents include, for example alkyl or aralkyl halides such as methyl or benzyl iodide and dialkyl sulphates such as dimethyl or diethylsulphate. Suitable strong bases include, for example, sodium hydride, lithium diisopropylamide or dimsyl sodium (the sodium salt of dimethyl sulphoxide). Subsequent removal of any protecting groups present affords the desired compounds of structure (I).

The intermediates of structure (II), (IV), (VI), (VII) and (VIII) can be prepared by standard techniques.

The intermediates of structure (III) and (V) are commercially available or can be prepared by standard techniques.

55 The compounds of structure (I) and their pharmaceutically acceptable salts exert an anti-secretory effect by inhibition of the gastrointestinal H^+K^+ ATPase enzyme (Fellenius, E., Berglinth, T., Sachs, G., Olke, L., Elander, B., Sjostrand, S.E., and Wallmark, B., 1981, Nature, 290, 159-61).

In a further aspect therefore the present invention provides compounds of structure (I) and pharmaceutically acceptable salts thereof for use in therapy. The compounds of structure (I) and their pharmaceutically

acceptable salts inhibit exogenously and endogenously stimulated gastric acid secretion and are useful in the treatment of gastrointestinal diseases in mammals, in particular humans. Such diseases include, for example, gastric and duodenal ulcers, aspiration pneumonitis and Zollinger-Ellison Syndrome.

Further, the compounds of structure (I) can be used in the treatment of other disorders where an anti-secretory effect is desirable for example in patients with gastritis, NSAID induced gastritis, acute upper intestinal bleeding, in patients with a history of chronic and excessive alcohol consumption, and in patients with gastro oesophageal reflux disease (GERD).

In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The compounds of structure (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example, ethanol, glycerine, non-aqueous solvent, for example, polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.

Preferably the composition is in unit dose form such as a tablet or capsule.

Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.

The present invention also provides a method of inhibiting gastric acid secretion which comprises administering to a mammal in need thereof an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof; and a method of treatment of diseases of the stomach or intestine based on increased acid secretion which comprises administering to a mammal in need thereof an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

The pharmaceutically acceptable compounds of the invention will normally be administered to a subject for the treatment of gastro-intestinal diseases and other conditions caused or exacerbated by gastric acidity. The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.

In addition, the compounds of the present invention can be co-administered with further active ingredients, such as antacids (for example magnesium carbonate or hydroxide and aluminium hydroxide), non-steroidal anti-inflammatory drugs (for example indomethacin, aspirin or naproxen), steroids, or nitrite scavengers (for example ascorbic acid or aminosulphonic acid), or other drugs used for treating gastric ulcers (for example pirenzepine, prostanoids for example 16,16 dimethyl PGE₂, or histamine H₂-antagonists (for example, cimetidine).

The following Examples illustrate the invention. Temperatures are recorded in degrees centigrade.

Example 1Ethyl 8-methoxy-4-(4-methyl-3-thienylamino)quinoline 3-carboxylate

The sodium salt of 3-amino-4-methylthiophene-2-carboxylic acid (7.2 g, 0.04 mol) and ethyl 8-methoxy-4-chloroquinoline-3-carboxylate (5.39 g, 0.02 mol) in toluene (75 ml), ethanol (55 ml) and glacial acetic acid (10 ml) were stirred at room temperature for five days. The solvents were removed by evaporation at reduced pressure to give a dark-green slurry. 10% aqueous sodium carbonate was added and the insoluble solid filtered off, washed well with water and dried. This material was crystallised from ethyl acetate (with charcoaling) to give the title compound as pale yellow crystals (2.15 g), m.p. 162-164°.

C ₁₈ H ₁₈ N ₂ O ₃ S				
Found	C, 63.19;	H, 5.32;	N, 8.20;	S, 9.23%
Requires	C, 63.14;	H, 5.30;	N, 8.18;	S, 9.36%

Example 23-Butyryl-4-(2-ethyl-3-thienylamino)-8-methoxyquinoline

a) Methyl 4-amino-5-ethylthiophene-2-carboxylate hydrochloride (5 g, 0.023 mol) and sodium hydroxide solution (2N, 25 ml) were heated under reflux for one hour. Evaporation under reduced pressure gave a solid sodium salt of -COOH, of which (2.2 g, 0.0113 mol) was suspended in toluene (50 ml) containing a solution of 3-butyryl-4-chloro-8-methoxyquinoline (1.5 g, 0.0057 mol) in ethanol (20 ml). Glacial acetic acid (1 ml) was added and the reaction mixture was stirred at room temperature for five days. The solvents were removed under reduced pressure and the residue basified with dilute sodium carbonate solution. The resulting solid was collected by filtration and dried, 1.85 g, m.p. 228°-232°.

b) 5-Ethyl-4-(4-(8-methoxyquinolyl)amino)thiophene-3-carboxylic acid (1.44 g, 0.00362 mol) and copper-bronze (0.3 g) in quinoline (30 ml) was heated under reflux for fifteen minutes. Chloroform (300 ml) was added to the cooled mixture and the copper filtered off over Hiflo. The chloroform was extracted with 2N.HCl (5 x 150 ml). The chloroform extracts were then washed with aqueous sodium bicarbonate and water, dried and evaporated to dryness to give a brown-yellow oil which solidified on standing. This material was crystallised twice from acetone to give the title compound as yellow crystals (0.42 g), m.p. 119-121°.

C ₂₀ H ₂₂ N ₂ O ₂ S				
Found	C, 67.38;	H, 6.25;	N, 7.89;	S, 9.08%
Requires	C, 67.77;	H, 6.26;	N, 7.40;	S, 9.05%

Example 33-Butyryl-4-(2-methoxycarbonyl-3-thienylamino)-8-methoxyquinoline

3-Butyryl-4-chloro-8-methoxyquinoline (0.5 g, 0.0019 mol) and methyl 3-aminothiophene-2-carboxylate (0.6 g, 0.0038 mol) were heated in an oil bath at 140° for one hour. After cooling the residual solid was dissolved in chloroform and the chloroform solution extracted with 2N.HCl (3 x 50 ml). The chloroform solution was then washed with aqueous sodium carbonate solution (x 2) and water, dried and evaporated to

give a yellow solid residue. This was crystallised (with charcoaling) from absolute ethanol to give the title compound as a yellow solid (0.55 g), m.p. 159-161°.

C ₂₀ H ₂₀ N ₂ O ₄ S				
Found	C, 62.22;	H, 5.10;	N, 7.24;	S, 8.42%
Requires	C, 62.48;	H, 5.24;	N, 7.29;	S, 8.34%

Example 4

3-Butyryl-4-(3-methyl-2-thienylamino)-8-methoxyquinoline

3-Butyryl-4-chloro-8-methoxyquinoline (3.6 g, 0.0137 mol) and 2-amino-3-methylthiophene (3.4 g, 0.03 mol) in 1,4 dioxan (30 ml) under a nitrogen atmosphere were stirred at room temperature for 20 hours. The solvent was evaporated under reduced pressure to give an oil. The oil was taken up in dichloromethane and extracted with 2N hydrochloric acid (3 x 100ml). The dichloromethane extracts were then washed with sodium carbonate solution (100 ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to give a solid. The solid was purified by flash chromatography using a gradient elution of dichloromethane/methanol (0-5%, 500 ml). The fractions containing the product were combined and evaporated under reduced pressure to give a solid, (1.94 g), m.p. 130-132°. Recrystallization from ethyl acetate gave the title compound, (1.7 g), m.p. 132-133°.

C ₁₉ H ₂₀ N ₂ O ₂ S				
Found	C 66.89,	H 5.93,	N 8.25,	S 9.35%
Requires	C 67.03,	H 5.92,	N 8.23,	S 9.42%

Example 5

Ethyl 8-methoxy-4-(4-methoxy-3-thienylamino)quinoline-3-carboxylate

Ethyl 8-methoxy-4-chloroquinoline-3-carboxylate (1.5 g, 0.0056 mol) and 4-methoxy-3-aminothiophene (1.46 g, 0.0112 mol) in 1,4 dioxan (20 ml) were heated under reflux for 4 hours. The solid which had formed was collected by filtration and dried. The solid was dissolved in chloroform, washed with sodium carbonate solution (50 ml), then water, dried over magnesium sulphate, filtered and evaporated under reduced pressure to give a yellow solid. Recrystallization from ethyl acetate gave the title compound, (1.53 g) m.p. 176-178°.

C ₁₈ H ₁₈ N ₂ O ₄ S				
Found	C 60.47,	H 5.18,	N 7.84,	S 8.71%
Requires	C 60.32,	H 5.06,	N 7.82,	S 8.95%

Example A

A tablet for oral administration is prepared by combining

	Mg/Tablet
Compound of structure (I)	100
lactose	153
Starch	33
crospovidone	12
microcrystalline cellulose	30
magnesium stearate	2
	<u>330 mg</u>

into a 9 mm tablet.

Example B

An injection for parenteral administration is prepared from the following

	%w:w
Compound of Structure (I)	0,50% (w:v)
1M citric acid	30% (v:v)
sodium hydroxide (qs)	to pH 3.2
water for injection EP	to 100 ml

The compound of Structure (I) is dissolved in the citric acid and the pH slowly adjusted to pH 3.2 with the sodium hydroxide solution. The solution is then made up to 100 ml with water, sterilised by filtration and sealed into appropriately sized ampoules and vials.

Biological Data

A. H^+K^+ ATPase Activity

The effects of a single high concentration (100 μ M) of a compound of structure (I) on K-stimulated ATPase activity in lyophilised gastric vesicles was determined. Preferred compounds of structure (I) were also tested over a range of concentrations to determine IC_{50} values.

(i) Preparation of lyophilised gastric vesicles (H/K-ATPase)

Lyophilised gastric vesicles were prepared from pig fundic mucosa after the method of Keeling et. al. (Biochem. Pharmacol., 34, 2967, 1985).

(ii) K^+ -stimulated ATPase activity

K^+ -stimulated ATPase activity was determined at 37° in the presence of the following : 10 mM Pipes-Tris buffer pH 7.0, 2 mM $MgSO_4$, 1 mM KCl, 2 mM Na_2ATP and 3-6 μ g protein/ml lyophilised gastric vesicles. After incubation for 30 minutes, the inorganic phosphate hydrolysed from ATP was determined by the method of Yoda and Hokin (Biochem. Biophys. Res. Commun. 40, 880, 1970).

Compounds of structure (I) were dissolved in dimethylsulphoxide which up to the highest concentration used had no effect on K^+ -stimulated ATPase activity.

The effect of the highest concentration of each compound of structure (I) on the recovery of a standard amount of inorganic phosphate was also determined.

The results obtained are shown in the following table:

Example No.	ATPase IC ₅₀ (μ M)
1	0.53
2	1.4
3	21% @ 100 μ M
4	2.3
5	3.4


B. Rat Lumen Perfused Stomach (pentagastrin stimulated gastric acid secretion).

Using a modification of the procedure described by Ghosh & Schild (Br. J. Pharmacology, 13, 54, 1958), the compounds of the following examples were found on i.v. administration at a concentration of 10 μ mole/kg to cause an inhibition of pentagastrin stimulated gastric acid secretion as indicated in the following table. Results are given as % inhibition at 10 μ mole/kg or ED₅₀ (μ M/kg):

Example No.	ED ₅₀ (μ M/Kg) % inhibition
1	4.62
2	61%
3	48%
4	58%
5	41%

Claims

1. A compound of structure (I) :



in which

- R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxylC₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, phenyl, phenylC₁₋₆alkyl, the phenyl groups being optionally substituted;
 R² is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂H or CO₂C₁₋₆alkyl;
 m is 1, 2 or 3;
 p is 0 to 4;
 R³ is hydrogen, C₁₋₆alkyl, phenyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, di-C₁₋₆alkylamino, halogen, trifluoromethyl or cyano;
 n is 1 or 2; and
 X is S, O, NH or NC₁₋₄alkyl;

or a salt thereof.

2. A compound according to claim 1 in which the heterocyclic ring is bonded to the nitrogen via the 3-position of said ring.

3. A compound according to claim 2 in which m is 1 and R² is hydrogen.

4. A compound according to claim 3 in which n is 1 and R³ is a C₁₋₆ alkyl or C₁₋₆ alkoxy group.

5. A compound according to claim 4 in which the group R³ is in the 8-position of the quinoline ring.

6. A compound according to claim 5 which is

ethyl 8-methoxy-4-(4-methyl-3-thienylamino)quinoline 3-carboxylate

3-butyryl-4-(2-ethyl-3-thienylamino)-8-methoxyquinoline

3-butyryl-4-(2-methoxycarbonyl-3-thienylamino)-8-methoxyquinoline

3-butyryl-4-(3-methyl-2-thienylamino)-8-methoxyquinoline,

or

ethyl 8-methoxy-4-(4-methoxy-3-thienylamino)quinoline-3-carboxylate,

or a salt thereof.


7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

8. A compound according to any one of claims 1 to 6 for use in therapy.


9. A compound according to any one of claims 1 to 6 for use in the inhibition of gastric acid secretion.

10. A process for the preparation of a compound according to claim 1 which comprises

(a) reaction of a compound of structure (II) with a compound of structure (III) :




(II)




(III)

in which R¹, R², R³, n, m, p, and X are as described for structure (I) and Y is a group displaceable by an amine:

(b) for compounds in which p is 1 to 4, reaction of a compound of structure (IV) with a compound of structure (V) :




(IV)



(V)


in which R¹, R², R³, n, m and X are as described for structure (I) and Y¹ is a group displaceable by an amine:

(c) reduction of a compound of structure (VI) :



15 in which R^1 , R^2 , R^3 , n , m , p and X are as described for structure (I); and R^4 is hydrogen or a nitrogen protecting group;

20 (d) for compounds of structure (I) in which R^1 is other than C_{1-6} alkoxy, oxidation of a compound of structure (VII)



35 in which R^2 , R^3 , p and n are as described for structure (I), $R^{1'}$ is a group R^1 other than C_{1-6} alkoxy and R^4 is hydrogen or a nitrogen protecting group; and thereafter if desired,


- 40
- removing any protecting groups;
 - converting a group R^1 into another group R^1 ;
 - converting a group R^2 into another group R^2 ;
 - forming a salt.

45 Claims for the following Contracting States: ES, GR.

1. A process for preparing a compound of structure (I):

50

55



15 in which

R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxylC₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, phenyl, phenylC₁₋₆alkyl, the phenyl groups being optionally substituted;

R² is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂H or CO₂C₁₋₆alkyl;

20 m is 1, 2 or 3;

p is 0 to 4;



R³ is hydrogen, C₁₋₆alkyl, phenyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, di-C₁₋₆alkylamino, halogen, trifluoromethyl or cyano;

n is 1 or 2; and

25 X is S, O, NH or NC₁₋₄alkyl;



or a salt thereof, which comprises

(a) reaction of a compound of structure (II) with a compound of structure (III) :




40 in which R¹, R², R³, n, m, p, and X are as described for structure (I) and Y is a group displaceable by an amine:

45 (b) for compounds in which p is 1 to 4, reaction of a compound of structure (IV) with a compound of structure (V) :




in which R^1 , R^2 , R^3 , n , m and X are as described for structure (I) and Y^1 is a group displaceable by an amine;

(c) reduction of a compound of structure (VI) :



20 in which R^1 , R^2 , R^3 , n , m , p and X are as described for structure (I); and R^4 is hydrogen or a nitrogen protecting group;

(d) for compounds of structure (I) in which R^1 is other than C_{1-6} alkoxy, oxidation of a compound of structure (VII)



40 in which R^2 , R^3 , p and n are as described for structure (I), $R^{1'}$ is a group R^1 other than C_{1-6} alkoxy and R^4 is hydrogen or a nitrogen protecting group; and thereafter if desired,

- removing any protecting groups;
- converting a group R^1 into another group R^1 ;
- converting a group R^2 into another group R^2 ;
- forming a salt.

45

2. A process according to claim 1(a) in which the reaction is carried out in a solvent.

3. A process according to claim 2 in which the solvent is 1,4-dioxan.

4. A process according to claim 3 in which in the compound of structure (I) the heterocyclic ring is bonded to the nitrogen via the 3-position of said ring.

50 5. A compound according to claim 4 in which in the compound of structure (I) m is 1 and R^2 is hydrogen.

6. A compound according to claim 5 in which in the compound of structure (I) n is 1 and R^3 is a C_{1-6} alkyl or C_{1-6} alkoxy group.

7. A compound according to claim 6 in which in the compound of structure (I) the group R^3 is in the 8-position of the quinoline ring.

55 8. A compound according to claim 7 in which the compound of structure (I) is
ethyl 8-methoxy-4-(4-methyl-3-thienylamino)quinoline 3-carboxylate
3-butyryl-4-(2-ethyl-3-thienylamino)-8-methoxyquinoline

3-butyryl-4-(2-methoxycarbonyl-3-thienylamino-8-methoxyquinoline
 3-butyryl-4-(3-methyl-2-thienylamino)-8-methoxyquinoline,
 or
 ethyl 8-methoxy-4-(4-methoxy-3-thienylamino)quinoline-3-carboxylate,
 5 or a salt thereof.

9. A process for preparing a pharmaceutical composition which comprises bringing into association a compound of structure (I) as described in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

10. A process according to claim 9 in which the compound of structure (I) is selected from

10 ethyl 8-methoxy-4-(4-methyl-3-thienylamino)quinoline 3-carboxylate
 3-butyryl-4-(2-ethyl-3-thienylamino)-8-methoxyquinoline
 3-butyryl-4-(2-methoxycarbonyl-3-thienylamino-8-methoxyquinoline
 3-butyryl-4-(3-methyl-2-thienylamino)-8-methoxyquinoline,
 or
 15 ethyl 8-methoxy-4-(4-methoxy-3-thienylamino)quinoline-3-carboxylate,
 or a pharmaceutically acceptable salt thereof.

20

25

30

35

40

45

50

55



EP 89 30 1800

DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)												
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 12, no. 6, November 1969, pages 1096-1097; J.W. HANIFIN et al.: "The synthesis of some 4-Anilino-3-quinolinecarboxylic acids and esters" * Page 1096, column 2, lines 17,18; page 1097, scheme 2, compound 20 * ---	1,7	C 07 D 409/12 C 07 D 405/12 C 07 D 401/12 A 61 K 31/47												
Y	GB-A-2 047 244 (A.H. ROBINS) * Page 1, lines 6-101; claims 1,46,48 * ---	1,7-9													
Y	US-A-2 652 398 (I.A. KAYE) * Column 1, lines 1-53; column 4, line 1 - column 5, line 55; claims 1,2 * ---	1,7-9													
P,Y D	EP-A-0 259 174 (SMITH KLINE & FRENCH LABORATORIES LTD) * Claims 1,9,10 * ---	1,7-9													
A	US-A-3 755 332 (J.W.F. WASLEY) * Column 1, lines 10-53; column 3, lines 57-66; claim 1 * -----	1,7-9	TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 07 D 409/00 C 07 D 405/00 C 07 D 401/00 C 07 D 215/00 A 61 K 31/00												
The present search report has been drawn up for all claims															
Place of search THE HAGUE		Date of completion of the search 23-05-1989	Examiner BRENNAN J.												
<table border="0"><tr><td>CATEGORY OF CITED DOCUMENTS</td><td>T : theory or principle underlying the invention</td></tr><tr><td>X : particularly relevant if taken alone</td><td>E : earlier patent document, but published on, or after the filing date</td></tr><tr><td>Y : particularly relevant if combined with another document of the same category</td><td>D : document cited in the application</td></tr><tr><td>A : technological background</td><td>L : document cited for other reasons</td></tr><tr><td>O : non-written disclosure</td><td>.....</td></tr><tr><td>P : intermediate document</td><td>& : member of the same patent family, corresponding document</td></tr></table>				CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention	X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date	Y : particularly relevant if combined with another document of the same category	D : document cited in the application	A : technological background	L : document cited for other reasons	O : non-written disclosure	P : intermediate document	& : member of the same patent family, corresponding document
CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention														
X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date														
Y : particularly relevant if combined with another document of the same category	D : document cited in the application														
A : technological background	L : document cited for other reasons														
O : non-written disclosure														
P : intermediate document	& : member of the same patent family, corresponding document														